Home Online Features Woolsey Pharmaceuticals Secures Additional Key U.S. Patent Claims for BRAVYL® (oral fasudil) in Treating ALS, Including Reducing Neurofilament Light (NfL)
Woolsey Pharmaceuticals Secures Additional Key U.S. Patent Claims for BRAVYL® (oral fasudil) in Treating ALS, Including Reducing Neurofilament Light (NfL)
Hand-out
Press Releases
Woolsey Pharmaceuticals, Inc.  
January 10, 2025

Woolsey Pharmaceuticals Secures Additional Key U.S. Patent Claims for BRAVYL® (oral fasudil) in Treating ALS, Including Reducing Neurofilament Light (NfL)

NEW YORK, Jan. 10, 2025 /PRNewswire/ -- Woolsey Pharmaceuticals, whose mission is to usher in a new era of neurodegenerative disease treatment, today announced that the U.S. Patent and Trademark

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social